MIRACLE Medical Technology Act of 2025

What happened and its current status: HR661, the MIRACLE Medical Technology Act, was introduced on January 23, 2025, by Representative Vern Buchanan (R-FL-16) with three cosponsors. The bill was referred to the House Committee on Energy and Commerce the same day and has had no subsequent actions — no hearings, markups, or floor votes in over 15 months. It remains in early-stage limbo typical of uncontroversial but unfunded authorizing bills. The money trail: The bill contains zero appropriated funding. The operative language reads 'Subject to the availability of appropriations,' meaning Congress must pass a separate appropriations bill to fund the collaboration program. Typical U.S.-Israel bilateral health programs (like the U.S.-Israel Binational Industrial R&D Foundation, BIRD) have annual appropriations in the $3-5 million range. Even if this bill passed, the market impact would be marginal for a sector worth hundreds of billions. Structural winners and losers: The bill's language is broad, covering medical device technology, biological products, digital health, and early-stage clinical trials. Potential long-term beneficiaries include large-cap med-tech companies with R&D exposure to Israel ($ISRG, $MDT), clinical CROs with Israeli operations (, ), and digital health firms. However, without funding, these are speculative connections. The Department of Health and Human Services is the obligated party, not private companies. Timeline: The legislative path is long. The bill must survive committee markup (not yet scheduled), pass the House, pass the Senate (no companion bill exists), and be signed into law. Then appropriators must fund it. The 119th Congress ends January 2027; this bill has almost no chance of enactment before then without significant committee chair support or addition to a must-pass package.